UNSPSC 51101641: Buparvaquone

This classification denotes an antiprotozoal agent with the molecular formula C21H26O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0354RT7LG4, chemically known as 1,4-naphthalenedione, 2-((4-(1,1-dimethylethyl)cyclohexyl)methyl)-3-hydroxy- but generally known as buparvaquone, which bears US NIH Compound Identifier 71768. European Medicines Agency schedules Buparvaquone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05980MIG.

UNSPSC 51101641 Buparvaquone is a Commodity code that, based on recent state and local solicitations, does not align with actual procurement activity under this category. The code nominally covers a specific veterinary pharmaceutical treatment for parasitic infections in animals, but the recent opportunities tagged to this code involve human health supplies—naloxone, drug deactivation systems, medical and first aid supplies for fire rescue operations, and generic pharmaceuticals through cooperative purchasing. The mismatch suggests either a cataloging error in the underlying procurement systems or that this code is being misapplied to human pharmaceutical and medical supply acquisitions. State and local issuing bodies posting under this code span county health departments, state health and human services commissions, municipal fire departments, and cooperative purchasing alliances serving multiple jurisdictions.

Recent opportunities include Seminole County, Florida's IFB for naloxone and safe drug deactivation systems (posted June 30, 2026, due July 26, 2023—a date discrepancy in the source); the City of Tampa's IFB for medical and first aid supplies for the Fire Department Rescue Division with an estimated contract value of $700,000 and SLBE set-asides (posted March 25, 2026, due March 13, 2026); the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products serving state and local facilities across Minnesota and Oregon (RFP posted January 20, 2026, due March 26, 2026); and the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs (posted April 3, 2026, same-day response deadline). Activity appears concentrated in the Southeast and Upper Midwest, though the MMCAP cooperative extends to Oregon. The code shows no genuine market activity aligned with its nominal scope; vendors should verify code assignment before pursuing opportunities posted under this classification.